Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Considers Pricing Flexibility For Avastin In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.

You may also be interested in...



Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer

The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.

Genentech Resubmits Avastin sBLA For Metastatic Breast Cancer

The targeted oncologic is simultaneously approved in Europe for first-line treatment of patients with advanced non-small cell lung cancer.

Genentech Plans Avastin Breast Cancer Resubmission In August

Company expects a six-month review for the supplemental claim, setting early 2008 for potential FDA approval.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel